Elumn8 Medical Secures Series C, Unveils New Identity for Advanced Heart Care
February 23, 2026, 4:11 pm
Elumn8 Medical, previously Simpson Interventions, completed initial Series C financing. The company also announced a strategic rebrand. This funding fuels clinical development of the Acolyte Image-Guided Catheter System. Acolyte targets challenging coronary chronic total occlusions (CTOs). It integrates optical coherence tomography (OCT) for real-time visualization. The technology aims to enhance precision, predictability, and safety in complex coronary interventions. A multi-site U.S. clinical trial progresses. The FDA recognized Acolyte with Breakthrough Device Designation. Elumn8 Medical focuses on pioneering image-enabled solutions for critical cardiovascular needs.
A significant shift is underway in medical technology. Elumn8 Medical, formerly Simpson Interventions, just finalized its initial Series C financing. This pivotal funding signals strong investor confidence. The company simultaneously unveiled a new corporate identity. This rebrand reflects a broadened vision for advanced coronary interventions.
The capital infusion will drive critical clinical development. It specifically targets the Acolyte Image-Guided Crossing and Re-Entry Catheter System. This innovative system is currently undergoing evaluation. A pre-market clinical trial assesses its efficacy and safety. The Acolyte system aims to treat coronary chronic total occlusions. These completely blocked coronary arteries present a persistent challenge. Interventional cardiologists frequently confront this complex condition. Standard procedures often struggle with these blockages.
Coronary chronic total occlusions (CTOs) represent a severe form of coronary artery disease. They can cause chest pain, shortness of breath, and reduced quality of life. Current treatments involve percutaneous coronary intervention (PCI). However, CTO PCI remains one of the most technically demanding procedures. Navigating completely occluded vessels requires immense skill. Physicians need precise tools. Elumn8 Medical’s Acolyte System seeks to provide these tools. It could revolutionize how these blockages are addressed.
The Acolyte System integrates groundbreaking technology. It provides real-time intravascular imaging. This feature supports controlled guidewire crossing. It also enables targeted re-entry. The goal is to restore blood flow beyond the lesion. Optical coherence tomography (OCT) imaging is key. It is integrated directly into the crossing and re-entry catheter. This dual visualization approach offers critical advantages. Physicians can view anatomy with unprecedented clarity. Concurrent fluoroscopy and OCT visualization enhances procedural control.
This integrated imaging aims for multiple improvements. It seeks to boost procedural efficiency. It promises greater predictability. Most importantly, it targets enhanced patient safety. These benefits are crucial for complex coronary interventions. Better visualization leads to more informed decisions. More precise wire delivery reduces risks. This advancement could transform outcomes for CTO patients.
The Acolyte System holds significant regulatory recognition. The FDA granted it Breakthrough Device Designation. This status is reserved for technologies offering more effective treatment. They must address life-threatening or irreversibly debilitating conditions. The FDA also accepted Acolyte into its Total Product Life Cycle Advisory Program (TAP). This program facilitates faster development and review. Both designations underscore the system's potential impact. They highlight an unmet medical need in coronary CTO treatment.
Clinical trials are progressing actively. The Acolyte pre-market clinical trial evaluates its safety and performance. Patients undergoing CTO percutaneous coronary intervention participate. The trial enrolls patients across multiple sites. These are located throughout the United States. Up to 103 patients are expected to join. Enrollment will span as many as 15 centers. These studies are vital. They gather evidence to support the system's eventual market availability.
The corporate rebrand to Elumn8 Medical is highly strategic. It reflects a broadened company focus. The new name emphasizes image-enabled technologies. This direction aims to improve precision and predictability. It also enhances the safety of complex coronary interventions. The name itself holds historical significance. It references the eighth medical device company. Dr. John B. Simpson founded all eight. His prior innovations profoundly shaped interventional cardiology. This legacy drives Elumn8 Medical forward.
Joe Knight leads Elumn8 Medical as Chief Executive Officer. The company commits to advancing image-enabled solutions. These solutions target complex coronary interventions. Their technologies enhance visualization. They improve control and procedural confidence. This focus remains on minimally invasive percutaneous treatments. Coronary chronic total occlusions are the initial priority.
The Acolyte System remains an investigational device. United States law currently limits it to investigational use only. It is not yet available for sale. This status is standard for breakthrough medical technologies. Extensive clinical data and regulatory approval are prerequisites. The ongoing trial is a critical step towards this goal.
Elumn8 Medical's recent actions mark a new chapter. The Series C funding provides vital resources. The rebrand solidifies a forward-looking identity. The Acolyte System addresses a critical gap in cardiology. It promises improved outcomes for patients with complex heart blockages. The company’s trajectory suggests a future of innovative cardiovascular care.
A significant shift is underway in medical technology. Elumn8 Medical, formerly Simpson Interventions, just finalized its initial Series C financing. This pivotal funding signals strong investor confidence. The company simultaneously unveiled a new corporate identity. This rebrand reflects a broadened vision for advanced coronary interventions.
The capital infusion will drive critical clinical development. It specifically targets the Acolyte Image-Guided Crossing and Re-Entry Catheter System. This innovative system is currently undergoing evaluation. A pre-market clinical trial assesses its efficacy and safety. The Acolyte system aims to treat coronary chronic total occlusions. These completely blocked coronary arteries present a persistent challenge. Interventional cardiologists frequently confront this complex condition. Standard procedures often struggle with these blockages.
Coronary chronic total occlusions (CTOs) represent a severe form of coronary artery disease. They can cause chest pain, shortness of breath, and reduced quality of life. Current treatments involve percutaneous coronary intervention (PCI). However, CTO PCI remains one of the most technically demanding procedures. Navigating completely occluded vessels requires immense skill. Physicians need precise tools. Elumn8 Medical’s Acolyte System seeks to provide these tools. It could revolutionize how these blockages are addressed.
The Acolyte System integrates groundbreaking technology. It provides real-time intravascular imaging. This feature supports controlled guidewire crossing. It also enables targeted re-entry. The goal is to restore blood flow beyond the lesion. Optical coherence tomography (OCT) imaging is key. It is integrated directly into the crossing and re-entry catheter. This dual visualization approach offers critical advantages. Physicians can view anatomy with unprecedented clarity. Concurrent fluoroscopy and OCT visualization enhances procedural control.
This integrated imaging aims for multiple improvements. It seeks to boost procedural efficiency. It promises greater predictability. Most importantly, it targets enhanced patient safety. These benefits are crucial for complex coronary interventions. Better visualization leads to more informed decisions. More precise wire delivery reduces risks. This advancement could transform outcomes for CTO patients.
The Acolyte System holds significant regulatory recognition. The FDA granted it Breakthrough Device Designation. This status is reserved for technologies offering more effective treatment. They must address life-threatening or irreversibly debilitating conditions. The FDA also accepted Acolyte into its Total Product Life Cycle Advisory Program (TAP). This program facilitates faster development and review. Both designations underscore the system's potential impact. They highlight an unmet medical need in coronary CTO treatment.
Clinical trials are progressing actively. The Acolyte pre-market clinical trial evaluates its safety and performance. Patients undergoing CTO percutaneous coronary intervention participate. The trial enrolls patients across multiple sites. These are located throughout the United States. Up to 103 patients are expected to join. Enrollment will span as many as 15 centers. These studies are vital. They gather evidence to support the system's eventual market availability.
The corporate rebrand to Elumn8 Medical is highly strategic. It reflects a broadened company focus. The new name emphasizes image-enabled technologies. This direction aims to improve precision and predictability. It also enhances the safety of complex coronary interventions. The name itself holds historical significance. It references the eighth medical device company. Dr. John B. Simpson founded all eight. His prior innovations profoundly shaped interventional cardiology. This legacy drives Elumn8 Medical forward.
Joe Knight leads Elumn8 Medical as Chief Executive Officer. The company commits to advancing image-enabled solutions. These solutions target complex coronary interventions. Their technologies enhance visualization. They improve control and procedural confidence. This focus remains on minimally invasive percutaneous treatments. Coronary chronic total occlusions are the initial priority.
The Acolyte System remains an investigational device. United States law currently limits it to investigational use only. It is not yet available for sale. This status is standard for breakthrough medical technologies. Extensive clinical data and regulatory approval are prerequisites. The ongoing trial is a critical step towards this goal.
Elumn8 Medical's recent actions mark a new chapter. The Series C funding provides vital resources. The rebrand solidifies a forward-looking identity. The Acolyte System addresses a critical gap in cardiology. It promises improved outcomes for patients with complex heart blockages. The company’s trajectory suggests a future of innovative cardiovascular care.